ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0591

Magnesium Supplements Reduce Arterial Stiffness in Patients with CKD Stage 3-4 but Do Not Affect Bone Mineral Density

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Pendon-Ruiz de Mier, Victoria, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Santamaria, Rafael, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Peregrin, Cayetana Moyano, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • López-López, Isabel, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Membrives González, Cristina, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Rodriguez Ortiz, Maria Encarnacion, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Gordillo Arnaud, Jose E., Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Chamizo, Asuncion Salmoral, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Munoz-Castaneda, Juan R., Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Rodelo-Haad, Cristian, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Martin-Malo, Alejandro, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Soriano Cabrera, Maria Sagrario, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
  • Rodriguez, Mariano, Hospital Universitario Reina Sofia, Cordoba, Andalucía, Spain
Background

Chronic Kidney Disease (CKD) entails to mineral metabolism disorders and vascular calcifications (VC). In vitro and in vivo, magnesium (Mg) supplements inhibits VC and show a beneficial effect on kidney function. However, some authors have suggested that Mg could affect bone turnover. We performed a study to evaluate the effect of dietary supplementation with Mg on arterial stiffness and bone mineral density in patients with CKD stage 3-4 and VC.

Methods

Randomized, open-label, parallel-group clinical trial (control/experimental) (n=8 per group). The experimental group received 360mg of Mg carbonate daily for 15±1.5 months. At the beginning and at the end of the study, blood and urinary biomarkers of bone mineral metabolism were measured; pulse wave velocity (PWV) was determined with Mobil-O-Graph device as an indicator of arterial stiffness, the Adragao index was calculated and bone mineral density was measured by densitometry.

Results

The included patients were in both groups mostly men and similar with respect to age and GFR. Serum Mg concentration were 1.9±0.1 vs 2±0.1mg/dl in control and experimental group respectively. At the baseline, no differences were found in demographic characteristics, comorbidities, treatments, PWV or biomarkers of bone mineral metabolism. The experimental group did not present hypermagnesemia or any other adverse event. The increase in urine Mg confirmed the therapeutic adherence. There was a decrease in GFR: 4ml/min in control and 1.71ml/min in experimental group, with no changes in serum Mg (both not statistically significant). An inverse correlation was found between urine Mg and the albumin/creatinine ratio (p=0.039). At the end of follow-up, serum Mg was inversely correlated with PWV (p=0.015). Urinary Mg was inversely correlated with iFGF23 (p=0.007). A non-significant trend of decrease in the Adragao index was observed in the experimental group. There were no changes in bone mineral density.

Conclusion

In CKD3-4 patients the Mg supplements reduce arterial stiffness without changes in bone mineral density.